Advancing Therapies for Serious Liver Disease
Altimmune (altimmune.com) earns a Brand Analyzer score of 81 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 3448 Healthcare brands analyzed, Altimmune ranks in the 83rd percentile (category average 72, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 91/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 93/100, AI Discoverability 85/100, Brand Authority 31/100.
Altimmune is an American late-stage biopharmaceutical company headquartered in Gaithersburg, founded in 1997. The company develops innovative therapeutics targeting the fundamental mechanisms driving serious liver disease progression. Its lead candidate, pemvidutide, uniquely combines dual glucagon receptor and GLP-1 activity to address both the causes and consequences of liver disease. Altimmune serves patients with significant unmet medical needs, alongside healthcare providers, investors, and industry partners.
| Brand Name | Altimmune |
|---|---|
| Domain | altimmune.com |
| Industry | Healthcare |
| Founded | 1997 |
| Headquarters | Gaithersburg |
| Main Competitors | Madrigal Pharmaceuticals (83/100), Viking Therapeutics (70/100), Novo Nordisk (88/100), Akero Therapeutics (74/100), 89bio (73/100), Eli Lilly (78/100), Boehringer Ingelheim (76/100) |
Moz Domain Authority 50/100 vs category average 35 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #662,588 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Altimmune is a late-stage biopharmaceutical company developing therapeutics to treat serious liver disease." (Meta description: 13 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, YouTube; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Altimmune scores 38/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Altimmune has a weak AI-visibility profile at 38/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (58/100) and its weakest is visibility (26/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #662,588 (Tranco) and a Moz Domain Authority of 50/100. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Altimmune from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Altimmune?", Claude could identify the brand as of August 2026. Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, liver disease, and other metabolic disorders, with its lead candidate pemvidutide being a GLP-1/glucagon dual receptor agonist. Best known for Developing pemvidutide, a dual GLP-1/glucagon receptor agonist being tested for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
When asked "Best brands similar to Altimmune?", Claude would recommend Altimmune as of August 2026. It's a relevant name in the competitive GLP-1 based obesity and liver disease drug development space alongside companies like Novo Nordisk and Eli Lilly, though it's earlier stage and smaller than those giants.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Altimmune's main competitors include Madrigal Pharmaceuticals (83/100), Viking Therapeutics (70/100), Novo Nordisk (88/100), Akero Therapeutics (74/100), 89bio (73/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Altimmune and Novo Nordisk are competitors in Healthcare. Brand Analyzer scores Altimmune at 81/100 and Novo Nordisk at 88/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Altimmune include Madrigal Pharmaceuticals (83/100), Viking Therapeutics (70/100), Novo Nordisk (88/100), Akero Therapeutics (74/100), 89bio (73/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Altimmune has limited AI-search visibility, scoring 38/100 on Brand Analyzer's AI visibility composite (visibility 26, trust 39, recommendation 58). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Altimmune official site
Altimmune was founded in 1997. Altimmune operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Altimmune is headquartered in Gaithersburg. Altimmune operates in the Healthcare category.
Sources: Wikidata
Altimmune scores 58/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Altimmune official site
Altimmune is a late-stage American biopharmaceutical company founded in 1997 and headquartered in Gaithersburg, Maryland. It focuses on developing innovative therapeutics that address serious liver disease, particularly conditions driven by complex metabolic mechanisms.
Sources: Altimmune official site
Altimmune develops therapeutics aimed at treating serious liver disease by targeting the fundamental biological mechanisms that drive disease progression. Its work centers on its lead candidate, pemvidutide, which combines dual glucagon receptor and GLP-1 receptor activity to address both the underlying causes and the physiological consequences of liver disease.
Sources: Altimmune official site
Altimmune can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Altimmune official site
Altimmune's primary offering is its late-stage drug candidate pipeline, most notably pemvidutide, a dual glucagon receptor and GLP-1 receptor agonist designed to treat serious liver disease by addressing both its underlying mechanisms and downstream effects. The company does not appear to offer commercial consumer products, as its work remains in the clinical development stage.
Sources: Altimmune official site
Altimmune is known for developing pemvidutide, a dual glucagon receptor and GLP-1 receptor agonist designed to treat serious liver disease by simultaneously addressing its causes and consequences. The company is recognized within the biopharmaceutical industry as a late-stage clinical-stage company focused on liver disease therapeutics.
Sources: Altimmune official site
Altimmune's therapeutics are intended for patients suffering from serious liver diseases with significant unmet medical needs. Additionally, the company engages with healthcare providers who may eventually administer its treatments, as well as investors and biopharmaceutical industry partners involved in funding and advancing its drug development programs.
Sources: Altimmune official site
Ranked closest to Altimmune: Alliant Insurance Services (81/100), Datavant (81/100), Amerigroup (81/100), AMN Healthcare (81/100).
A step up - brands to learn from: Oura (91/100), Olay (91/100).
Category leader: Elsevier (96/100).